4 not yet recruiting, 1 recruiting, 1 terminated, 1 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Not yet recruiting 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Not yet recruiting 3, Withdrawn 1 |
Follow AbelZeta Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL | Phase 2 | Not yet recruiting | AbelZeta Inc. | 55 | 2027-05-01 | 2026-10-15 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis | Phase 1 | Not yet recruiting | AbelZeta Inc. | 12 | 2027-03-01 | 2026-10-13 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy C-CAR168 - Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) | Phase 2 | Not yet recruiting | AbelZeta Inc. | 50 | 2026-09-30 | 2026-10-13 |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM) | Phase 1 | Recruiting | RenJi Hospital | 30 | 2024-03-20 | 2025-07-25 |
| C-TIL051 in Non-Small Cell Lung Cancer C-TIL051 - Metastatic Non Small Cell Lung Cancer | Phase 1 | Terminated | AbelZeta Inc. | 1 | 2024-02-29 | 2026-01-05 |
Lupus Erythematosus, Systemic (3) · Autoimmune Diseases (2) · Lupus Nephritis (2) · Multiple Sclerosis (2) · Scleroderma, Systemic (2) · Carcinoma, Non-Small-Cell Lung (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Multiple Sclerosis, Chronic Progressive (1) · Myasthenia Gravis (1) · Neuromyelitis Optica (1) · Scleroderma, Diffuse (1)
NKTR-255 (1) · pembrolizumab (1)
United States (5) · China (1)
Yihong Yao, PhD (3) · Nan Shen, MD & PhD (1) · Scott Antonia (1) · Scott Antonia, MD, PhD (1)